Data gathered: April 6
AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated March 27, 2025. Powered by Chat GPT.
Novo Nordisk is a global healthcare company with a long history of innovation and leadership in diabetes care. Founded in 1923 and headquartered in Denmark, the company has expanded its portfolio to include therapies for diabetes, obesity, hemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk also has a strong presence in more than 80 countries and its products are marketed in over 170 countries.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | April 6 Reddit mentions are up by 232% in the last 24h. |
|
Novo Nordisk | April 4 Price is down by -5.5% in the last 24h. |
|
Novo Nordisk | March 28 Reddit mentions are up by 150% in the last 24h. |
|
Novo Nordisk | March 25 News Alert: Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – NVO |
Alternative Data for Novo Nordisk
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $62.55 |
| Target Price | Sign up |
| Volume | 10,840,000 |
| Market Cap | $284B |
| Year Range | $62.55 - $136.99 |
| Dividend Yield | 2.58% |
| PE Ratio | 18.9 |
| Analyst Rating | 57% buy |
| Industry | Drug Manufacturers |
In the news
 |
Novo Nordisk readies to bring weight-loss drug Wegovy to IndiaApril 6 - The Times of India |
Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?April 4 - Yahoo Entertainment |
|
Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)April 3 - Yahoo Entertainment |
|
 |
Novo Nordisk Loses Another Executive as 28-Year Veteran DepartsApril 3 - Biztoc.com |
Novo Nordisk announces changes in Executive ManagementApril 2 - GlobeNewswire |
|
 |
Novo Nordisk: Not As Bullish As ManyApril 2 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 85.7B | 13B | 72.7B | 28.2B | 0 | 6.340 |
| Q3 '24 | 71.3B | 11.3B | 60B | 27.3B | 37.4B | 0.900 |
| Q2 '24 | 68.1B | 10.3B | 57.8B | 20.1B | 35.7B | 0.660 |
| Q1 '24 | 65.3B | 9.92B | 55.4B | 25.4B | 35.3B | 0.830 |
| Q4 '23 | 65.9B | 10B | 55.8B | 22B | 30.6B | 0.710 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$153.24 0% | 42 |
|
Eli Lilly and CompanyLLY |
$738.21 0% | 63 |
|
PfizerPFE |
$22.97 0% | 33 |
|
AstrazenecaAZN |
$68.46 0% | 51 |
|
AbbVieABBV |
$186.96 0% | 35 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Dec 18, 24 | Sell | $50K - $100K |
| Michael McCaul |
Nov 14, 24 | Buy | $15K - $50K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $284B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 18.9.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $62.55.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 2.58%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.